ArticleCentral-European journal of immunology2020
Th17 and regulatory T cells in patients with different time of progression of type 2 diabetes mellitus.
Article in Central-European journal of immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pooled it
- Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study.Frontiers in immunology · 2021Trial
- Role play of regulatory T cells and resolvins in type 2 diabetes.Frontiers in immunology · 2026Review
- Obesity and type 2 diabetes as chronic inflammation: how does the cytokine evidence align?Frontiers in endocrinology · 2026Review
- Intestinal CD4Molecular medicine reports · 2025Article
- Identification of comorbid genes between type 2 diabetes and migraine through peripheral blood single-cell and Mendelian randomization analysis.The journal of headache and pain · 2025Article
- Implication of serum soluble IL-2 receptor α in type 2 diabetes mellitus.Journal of diabetes and metabolic disorders · 2025Article
- Metabolic regulation of Th17/Treg balance.Central-European journal of immunology · 2025Article
- Meta-inflammation in type 2 diabetes mellitus: unveiling the role of aberrant CD4Frontiers in immunology · 2025Article
- Inulin andFrontiers in endocrinology · 2025Article
- Quantitative analysis of Tr1 lymphocytes in patients with type 2 diabetes mellitus.Journal of endocrinological investigation · 2024Article
- Age-related Differences in T-cell Subsets and Markers of Subclinical Inflammation in Aging Are Independently Associated With Type 2 Diabetes in the Health and Retirement Study.Canadian journal of diabetes · 2023Article
- Circulating cytokine profile and modulation of regulatory T cells in chronic hepatitis B patients with type 2 diabetes mellitus.Biomolecules & biomedicine · 2023Article
- Nitazoxanide Exerts Immunomodulatory Effects on Peripheral Blood Mononuclear Cells from Type 2 Diabetes Patients.Biomolecules · 2021Article
- Effector Memory CD8Pediatric gastroenterology, hepatology & nutrition · 2021Article
- The effects of helminth infections against type 2 diabetes.Parasitology research · 2021Review
- Dysregulation of circulating follicular helper T cells in type 2 diabetic patients with diabetic retinopathy.Immunologic research · 2021Article
- CD28null and Regulatory T Cells Are Substantially Disrupted in Patients with End-Stage Renal Disease Due to Diabetes Mellitus.International journal of molecular sciences · 2021Article
- Serum IL-36 cytokines levels in type 2 diabetes mellitus patients and their association with obesity, insulin resistance, and inflammation.Journal of clinical laboratory analysis · 2021Article
- The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes mellitus (T2DM) is characterized by chronic inflammation, in which different types of immune cells participate, such as TH17 cells and Treg cells. The aim of this study was to determine the relationship between Treg and Th17 in patients with different times of T2DM progression. MATERIAL AND
methodsNineteen control subjects and 40 patients with T2DM were included. T2DM patients were classified into two groups: the first group consisted of twenty patients with less than10 years of disease progression (T2DM < 10), and the second group included 20 patients with a disease progression of 10 years or more (T2DM ≥ 10). Additionally, an analysis was performed according to the metabolic control, depending on HbA1c levels. The peripheral blood ratio of both Th17 and Treg cells was measured by standard flow cytometry protocols.
resultsNo significant difference was found in Th17 cells of patients with T2DM < 10 or T2DM ≥ 10 and controls. With respect to CD4+CD25+FoxP3+ and CD4+CD25h Treg cells, a significant decrease was observed in patients with T2DM ≥ 10, mainly in patients with poor or moderate metabolic control. Statistical analysis performed in all patients with T2DM revealed a decrease in three cell subsets as well a negative correlation between Th17 cells and total cholesterol, CD4+CD25h cells with glucose and HbA1c levels, while a positive correlation was observed between CD4+CD25h cells and BMI.
conclusionsA decrease on both Treg and Th17 cell subsets in T2DM patients was observed suggesting that the metabolic decontrol and the progression time of T2DM could modify the proportions of Th17 and Treg cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.